Возможности лечения больных резистентной артериальной гипертензией

1. Wolf-Maier K, Cooper RS, Banegas JR et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada and the United States. JAMA 2003; 289 (18): 2363–9.
2. Turnbull F, Neal B, Ninomiya T et al. Efects of diferent regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ 2008; 336 (7653): 1121–3.
3. Lewington S, Clarke R, Qizilbash N et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360 (9349): 1903–13.
4. Bruno RM. Sympathetic regulation of vascular function in health and desease. Front Physiol 2012; 61 (2): 284.
5. Egan BM, Zhao Y, Axon RN et al. Uncontrolled and apparent treatment resistant hypertension in the U. S. 1988–2008. Circulation 2011; 124 (9): 1046–58.
6. Бойцов С.А., Баланова Ю.А., Шальнова С.А. и др. от имени участников исследования ЭССЕ-РФ. Кардиоваскулярная терапия и профилактика. 2014; 13 (4): 4–14. / Boitsov S.A., Balanova Yu.A., Shal'nova S.A. i dr. ot imeni uchastnikov issledovaniia ESSE-RF. Kardiovaskuliarnaia terapiia i profilaktika. 2014; 13 (4): 4–14. [in Russian]
7. Calhoun DA, Jones D, Textor S et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008; 51: 1403–19.
8. Roberie DR, Elliott WJ. What is the prevalence of resistant hypertension in the United States? Curr Opin Cardiol 2012; 27: 386–91.
9. Рекомендации Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов. Диагностика и лечение артериальной гипертензии. Российские рекомендации (пятый пересмотр). М., 2016.
10. ESH-ESC Guidelines committee. 2007 guidelines for the management of arterial hypertension. J Hypertens 2007; 25: 1105–87.
11. Алипов Н.Н. Основы медицинской физиологии. М., 2008. / Alipov N.N. Osnovy meditsinskoi fiziologii. M., 2008. [in Russian]
12. Prabhakar NR, Semenza GL. Gaseous messengers in oxygen sensing. J Mol Med 2012; 90: 265–72.
13. Guyton AC, Hall JE. Textbook of medical Physiology. 11 ed. Philadelphia: Elsevier Sounders, 2006; p. 216–28.
14. Бобров В.А. и др. Резистентная артериальная гипертензия: механизмы возникновения, диагностика и подходы к лечению (методические рекомендации). Киев, 2009. / Bobrov V.A. i dr. Rezistentnaia arterial'naia gipertenziia: mekhanizmy vozniknoveniia, diagnostika i podkhody k lecheniiu (metodicheskie rekomendatsii). Kiev, 2009. [in Russian]
15. Маргиева Т.В., Сергеева Т.В. Участие маркеров эндотелиальной дисфункции в патогенезе хронического гломерулонефрита. Вопр. современной педиатрии. 2006; 5 (3): 22–30. / Margieva T.V., Sergeeva T.V. Uchastie markerov endotelial'noi disfunktsii v patogeneze khronicheskogo glomerulonefrita. Vopr. sovremennoi pediatrii. 2006; 5 (3): 22–30. [in Russian]
16. Ющук Е.Н., Васюк Ю.А., Хадзегова А.Б. и др. Эндотелиальная дисфункция при заболеваниях сердечно-сосудистой системы и методы ее коррекции. Клин. фармакология и терапия. 2005; 14 (3): 85–8. / Yushchuk E.N., Vasyuk Yu.A., Khadzegova A.B. i dr. Endotelial'naia disfunktsiia pri zabolevaniiakh serdechno-sosudistoi sistemy i metody ee korrektsii. Klin. farmakologiia i terapiia. 2005; 14 (3): 85–8. [in Russian]
17. Panza JA, Quyyumi AA, Brush JE et al. Abnormal endothelium dependent vascular relaxation in patients with essential hypertension. New Engl J Med 1990; 323: 22–7.
18. Cushman WC, Ford CE, Cutler JA et al. For the ALLHAT Collaborative Research Group. Success and predictors of blood pressure control in diverse North American settings: the Antihypertensive and Lipid-Lowering and Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens 2002; 4: 393–404.
19. Ueda H, Uchida Y, Kamisaka K. Mechanisms of the reflex depressor effect by kidney in dog. Jpn Heart J 1967; 8: 597.
20. Calaresu FR, Kim P, Nakamura H et al. Electrophysiological characteristics of renorenal reflexes in the cat. J Physiol 1978; 283: 141.
21. Mahfoud F, Elazer R, Edelman MD, Böhm M et al. Catheter-Based Renal Denervation Is No Simple Matter. JACC 2014; 64 (7): 644–6.
22. Marshall EK, Kolls AC. Studies on the nervous control of the kidney in relation to diuresis and urinary secretion. I. The effect of unilateral excision of the adrenal, section of the splanchnic nerve and section of the renal nerves on the secretion of the kidney. Am J Physiol 1919; 49: 302.
23. Bernard C. Lecons sur les proprietesphysiologiqueset les alterations pathologiques des liquides de l'organisme. Paris, Baillière, 1859.
24. Bradford J. The innervation of the renal blood vessels. J Physiol 1889; 10: 358–432.
25. Sen S. Some observations on decapsulation and denervation of the kidney. Brit J Urol 1936; 8: 319–28.
26. Winternitz SR, Katholi RE, Oparil S. Role of the renal sympathetic nerves in the development and maintenance of hypertension in the spontaneously hypertensive rat. J Clin Invest 1980; 66: 971.
27. Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension 2011; 57: 911–7.
28. Esler MD, Böhm M, Sievert H et al. Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36 month results from the SYMPLICITY HTN-2 randomized clinical trial. Eur Heart J 2014; 35 (26): 1752–9. DOI: 10.1093/eurheartj/ehu209
29. Krum H, Schlaich MP, Sobotka PA et al. Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the SYMPLICITY HTN-1 study. Lancet 2014; 383: 622–9.
30. Mahfoud F, Böhm M, Azizi M et al. Proceedings from the European clinical consensus conference for renal denervation: considerations on future clinical trial design. Eur Heart J 2015; 36 (33): 2219–27.
31. Whitbourn RJ, Walton T, Harding S. TCT-408: Renal artery denervation with a new simultaneous multielectrode catheter for treatment of resistant hypertension: 12-month update from the SYMPLICITY Spyral first-in-man study. J Am Coll Cardiol 2014; 64 (11_S). DOI: 10.1016/j.jacc.2014.07.458
32. Verheye S. TCT-62: Preliminary Result of the Rapid Renal Sympathetic Denervation for Resistant Hypertension Using the Maya Medical OneShotTM Ablation System (RAPID) Study. J Am Coll Cardiol 2013; 62 (18, suppl. 1): B20.
33. Worthley SG, Tsioufis CP, Worthley MI et al. Safety and efficacy of a multi-electrode renal sympathetic denervation system in resistant hypertension: the EnligHTN I trial. Eur Heart J 2013; 34: 2132–40.
34. Marlborough MA. New data continue to show significant and sustained blood pressure reduction with Boston Scientific VessixTM Renal Denervation System (press release). Boston Scientific: October 28, 2013.
35. Sivert H, Schofer J, Ormiston J et al. Bipolar radiofreqency renal denervation with the Vessix catheter in patients with resistant hypertension: 2-years results from the REDUCE-HTN trial. J Hum Hyperten 2017; 31: 366–8.
36. Mabin T, Sapoval M, Cabane V et al. First experience with endovascular ultrasound renal denervation for the treatment of resistant hypertension. Euro Intervention 2012; 8: 57–61.
37. Neuzil P, Ormiston J, Brinton TJ. Externally Delivered Focused Ultrasound for Renal Denervation. JACC: Cardiovascular Interventions. J Am Coll Cardiol 2016; 9 (12). DOI: 10.1016/j.jcin.2016.04.013
38. Fischell TA, Vega F, Raju N et al. Ethanol-mediated perivascular renal sympathetic denervation: preclinical validation of safety and efficacy in a porcine model. Euro Intervention 2013; 9: 140–7.
39. Allen EV. Sympathectomy for Essential Hypertension. Circulation 1952; 6: 131–40.
40. Stuart M. Masterminds of Ardian: An Interview With Inventors Mark Gelfand and Howard Levin. Start-Up. 2011.
41. Schmieder RE, Redon J, Grassi G et al. ESH Position Paper: renal denervation – an interventional therapy of resistant hypertension. J Hypertens 2012; 30 (5).
42. Schlaich M, Sobotka P, Krum H et al. Renal denervation as a therapeutic approach for hypertension: novel implications for an old concept. Hypertension 2009; 54: 1195–201.
43. Ernst ME, Carter BL, Basile JN. All thiazide-like diuretics are not chlorthalidone: putting the ACCOMPLISH study into perspective. J Clin Hypertens (Greenwich) 2009; 11 (1): 5–10.
44. Pitt B, Zannad F, Remme WJ et al. For the Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on the morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709–17.
45. Wiysonge CS, Bradley H, Mayosi BM et al. Review Beta-blockers for hypertension. Cochrane Database Syst Rev 2007; 24 (1): CD002003.

________________________________________________

1. Wolf-Maier K, Cooper RS, Banegas JR et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada and the United States. JAMA 2003; 289 (18): 2363–9.
2. Turnbull F, Neal B, Ninomiya T et al. Efects of diferent regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ 2008; 336 (7653): 1121–3.
3. Lewington S, Clarke R, Qizilbash N et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360 (9349): 1903–13.
4. Bruno RM. Sympathetic regulation of vascular function in health and desease. Front Physiol 2012; 61 (2): 284.
5. Egan BM, Zhao Y, Axon RN et al. Uncontrolled and apparent treatment resistant hypertension in the U. S. 1988–2008. Circulation 2011; 124 (9): 1046–58.
6. Boitsov S.A., Balanova Yu.A., Shal'nova S.A. i dr. ot imeni uchastnikov issledovaniia ESSE-RF. Kardiovaskuliarnaia terapiia i profilaktika. 2014; 13 (4): 4–14. [in Russian]
7. Calhoun DA, Jones D, Textor S et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008; 51: 1403–19.
8. Roberie DR, Elliott WJ. What is the prevalence of resistant hypertension in the United States? Curr Opin Cardiol 2012; 27: 386–91.
9. Рекомендации Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов. Диагностика и лечение артериальной гипертензии. Российские рекомендации (пятый пересмотр). М., 2016.
10. ESH-ESC Guidelines committee. 2007 guidelines for the management of arterial hypertension. J Hypertens 2007; 25: 1105–87.
11. Alipov N.N. Osnovy meditsinskoi fiziologii. M., 2008. [in Russian]
12. Prabhakar NR, Semenza GL. Gaseous messengers in oxygen sensing. J Mol Med 2012; 90: 265–72.
13. Guyton AC, Hall JE. Textbook of medical Physiology. 11 ed. Philadelphia: Elsevier Sounders, 2006; p. 216–28.
14. Bobrov V.A. i dr. Rezistentnaia arterial'naia gipertenziia: mekhanizmy vozniknoveniia, diagnostika i podkhody k lecheniiu (metodicheskie rekomendatsii). Kiev, 2009. [in Russian]
15. Margieva T.V., Sergeeva T.V. Uchastie markerov endotelial'noi disfunktsii v patogeneze khronicheskogo glomerulonefrita. Vopr. sovremennoi pediatrii. 2006; 5 (3): 22–30. [in Russian]
16. Yushchuk E.N., Vasyuk Yu.A., Khadzegova A.B. i dr. Endotelial'naia disfunktsiia pri zabolevaniiakh serdechno-sosudistoi sistemy i metody ee korrektsii. Klin. farmakologiia i terapiia. 2005; 14 (3): 85–8. [in Russian]
17. Panza JA, Quyyumi AA, Brush JE et al. Abnormal endothelium dependent vascular relaxation in patients with essential hypertension. New Engl J Med 1990; 323: 22–7.
18. Cushman WC, Ford CE, Cutler JA et al. For the ALLHAT Collaborative Research Group. Success and predictors of blood pressure control in diverse North American settings: the Antihypertensive and Lipid-Lowering and Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens 2002; 4: 393–404.
19. Ueda H, Uchida Y, Kamisaka K. Mechanisms of the reflex depressor effect by kidney in dog. Jpn Heart J 1967; 8: 597.
20. Calaresu FR, Kim P, Nakamura H et al. Electrophysiological characteristics of renorenal reflexes in the cat. J Physiol 1978; 283: 141.
21. Mahfoud F, Elazer R, Edelman MD, Böhm M et al. Catheter-Based Renal Denervation Is No Simple Matter. JACC 2014; 64 (7): 644–6.
22. Marshall EK, Kolls AC. Studies on the nervous control of the kidney in relation to diuresis and urinary secretion. I. The effect of unilateral excision of the adrenal, section of the splanchnic nerve and section of the renal nerves on the secretion of the kidney. Am J Physiol 1919; 49: 302.
23. Bernard C. Lecons sur les proprietesphysiologiqueset les alterations pathologiques des liquides de l'organisme. Paris, Baillière, 1859.
24. Bradford J. The innervation of the renal blood vessels. J Physiol 1889; 10: 358–432.
25. Sen S. Some observations on decapsulation and denervation of the kidney. Brit J Urol 1936; 8: 319–28.
26. Winternitz SR, Katholi RE, Oparil S. Role of the renal sympathetic nerves in the development and maintenance of hypertension in the spontaneously hypertensive rat. J Clin Invest 1980; 66: 971.
27. Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension 2011; 57: 911–7.
28. Esler MD, Böhm M, Sievert H et al. Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36 month results from the SYMPLICITY HTN-2 randomized clinical trial. Eur Heart J 2014; 35 (26): 1752–9. DOI: 10.1093/eurheartj/ehu209
29. Krum H, Schlaich MP, Sobotka PA et al. Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the SYMPLICITY HTN-1 study. Lancet 2014; 383: 622–9.
30. Mahfoud F, Böhm M, Azizi M et al. Proceedings from the European clinical consensus conference for renal denervation: considerations on future clinical trial design. Eur Heart J 2015; 36 (33): 2219–27.
31. Whitbourn RJ, Walton T, Harding S. TCT-408: Renal artery denervation with a new simultaneous multielectrode catheter for treatment of resistant hypertension: 12-month update from the SYMPLICITY Spyral first-in-man study. J Am Coll Cardiol 2014; 64 (11_S). DOI: 10.1016/j.jacc.2014.07.458
32. Verheye S. TCT-62: Preliminary Result of the Rapid Renal Sympathetic Denervation for Resistant Hypertension Using the Maya Medical OneShotTM Ablation System (RAPID) Study. J Am Coll Cardiol 2013; 62 (18, suppl. 1): B20.
33. Worthley SG, Tsioufis CP, Worthley MI et al. Safety and efficacy of a multi-electrode renal sympathetic denervation system in resistant hypertension: the EnligHTN I trial. Eur Heart J 2013; 34: 2132–40.
34. Marlborough MA. New data continue to show significant and sustained blood pressure reduction with Boston Scientific VessixTM Renal Denervation System (press release). Boston Scientific: October 28, 2013.
35. Sivert H, Schofer J, Ormiston J et al. Bipolar radiofreqency renal denervation with the Vessix catheter in patients with resistant hypertension: 2-years results from the REDUCE-HTN trial. J Hum Hyperten 2017; 31: 366–8.
36. Mabin T, Sapoval M, Cabane V et al. First experience with endovascular ultrasound renal denervation for the treatment of resistant hypertension. Euro Intervention 2012; 8: 57–61.
37. Neuzil P, Ormiston J, Brinton TJ. Externally Delivered Focused Ultrasound for Renal Denervation. JACC: Cardiovascular Interventions. J Am Coll Cardiol 2016; 9 (12). DOI: 10.1016/j.jcin.2016.04.013
38. Fischell TA, Vega F, Raju N et al. Ethanol-mediated perivascular renal sympathetic denervation: preclinical validation of safety and efficacy in a porcine model. Euro Intervention 2013; 9: 140–7.
39. Allen EV. Sympathectomy for Essential Hypertension. Circulation 1952; 6: 131–40.
40. Stuart M. Masterminds of Ardian: An Interview With Inventors Mark Gelfand and Howard Levin. Start-Up. 2011.
41. Schmieder RE, Redon J, Grassi G et al. ESH Position Paper: renal denervation – an interventional therapy of resistant hypertension. J Hypertens 2012; 30 (5).
42. Schlaich M, Sobotka P, Krum H et al. Renal denervation as a therapeutic approach for hypertension: novel implications for an old concept. Hypertension 2009; 54: 1195–201.
43. Ernst ME, Carter BL, Basile JN. All thiazide-like diuretics are not chlorthalidone: putting the ACCOMPLISH study into perspective. J Clin Hypertens (Greenwich) 2009; 11 (1): 5–10.
44. Pitt B, Zannad F, Remme WJ et al. For the Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on the morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709–17.
45. Wiysonge CS, Bradley H, Mayosi BM et al. Review Beta-blockers for hypertension. Cochrane Database Syst Rev 2007; 24 (1): CD002003.

З.Х.Шугушев, Д.А.Максимкин, А.С.Рюмина*

ФГАОУ ВО «Российский университет дружбы народов». 117198, Россия, Москва, ул. Миклухо-Маклая, д. 6
*ryumina.anna@gmail.com

________________________________________________

Z.Kh.Shugushev, D.A.Maximkin, A.S.Ryumina*

People’s Friendship University of Russia. 117198, Russian Federation, Moscow, ul. Miklukho-Maklaya, d. 6
*ryumina.anna@gmail.com